The anti-tubercular activity of simvastatin is mediated by cholesterol-driven autophagy via the AMPK-mTORC1-TFEB axis
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Journal of Lipid Research
- Vol. 61 (12) , 1617-1628
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Institutes of Health (UH2/3 AI122309, R01 HL149450, R01 AI104615, UL1 TR003017)
- New Jersey Health Foundation (PC 10-15)
This publication has 83 references indexed in Scilit:
- Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammationProceedings of the National Academy of Sciences, 2012
- Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosisThe Pharmacogenomics Journal, 2012
- Cholesterol Catabolism by Mycobacterium tuberculosis Requires Transcriptional and Metabolic AdaptationsChemistry & Biology, 2012
- 3-Hydroxy-3-methylglutaryl–Coenzyme A Reductase Inhibitors in the Treatment of Central Nervous System DiseasesArchives of Neurology, 2010
- Cholesterol trafficking is required for mTOR activation in endothelial cellsProceedings of the National Academy of Sciences, 2010
- mTOR regulation of autophagyFEBS Letters, 2010
- The LKB1–AMPK pathway: metabolism and growth control in tumour suppressionNature Reviews Cancer, 2009
- Mycobacterial persistence requires the utilization of host cholesterolProceedings of the National Academy of Sciences, 2008
- Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein KinaseJournal of Biological Chemistry, 2007
- Anti-inflammatory and immunomodulatory effects of statinsKidney International, 2003